Clinical Trials
183
Active:8
Completed:73
Trial Phases
5 Phases
Early Phase 1:4
Phase 1:30
Phase 2:65
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (140 trials with phase data)• Click on a phase to view related trials
Phase 2
65 (46.4%)Not Applicable
34 (24.3%)Phase 1
30 (21.4%)Phase 3
7 (5.0%)Early Phase 1
4 (2.9%)This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer
Phase 2
Not yet recruiting
- Conditions
- Metastatic Non Small Cell Lung Cancer
- Interventions
- Drug: Scheduling of the time of pembrolizumab infusions
- First Posted Date
- 2025-03-18
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 58
- Registration Number
- NCT06882174
Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis
Phase 2
Not yet recruiting
- Conditions
- PneumonitisImmune-related Adverse Event
- Interventions
- Other: Arm 1- Usual careDrug: Arm 2- Budesonide (Pulmicort® Turbuhaler®) + Usual care
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 94
- Registration Number
- NCT06860542
GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma
- First Posted Date
- 2025-02-14
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 1
- Registration Number
- NCT06827886
- Locations
- 🇨🇦
Tom Baker Cancer Centre/Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Canada
COACH - Comparing Two Different Methods to Suppress Thyrotropin in Patients With Advanced Thyroid Cancer
Phase 2
Not yet recruiting
- Conditions
- Advanced Differentiated Thyroid Gland Carcinoma
- Interventions
- Drug: Levothyroxine Oral Tablet [Synthroid]
- First Posted Date
- 2025-01-24
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 70
- Registration Number
- NCT06790589
GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient with Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02)
- First Posted Date
- 2025-01-23
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 1
- Registration Number
- NCT06789081
- Prev
- 1
- 2
- 3
- 4
- 5
- 37
- Next
News
No news found